Spruce Biosciences, Inc. (SPRB) NASDAQ
49.30
-1.4(-2.76%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Spruce Biosciences, Inc.
Address
2001 Junipero Serra Boulevard
Daly City, CA 94014
United States of America (the)
Phone
415 655 4168
Sector
Healthcare
Industry
Biotechnology
Employees
20
First IPO Date
October 09, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Javier Szwarcberg | Chief Executive Officer & Director | 1.12M | 1970 |
| Michael G. Grey | Executive Chairman | 70,000 | 1953 |
| Kirk Ways | Chief Medical Officer & Director | 596,833 | 1953 |
| Samir Gharib | President & Chief Financial Officer | 784,043 | 1982 |
| Corwin Dale Hooks | Chief Commercial Officer | 0 | 1967 |
| Bruno Gagnon BPHARM | Senior Vice President of Clinical Development Operations | 0 | 1969 |
| Daven Mody | Senior Vice President of Regulatory & Quality | 0 | N/A |
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
